Should severe CAP patients receive anti-MRSA coverage? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017
Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Should macrolides be given to all patients with community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017
Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP? Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021 Year: 2021
How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017
Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure Year: 2018
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Should we change our antibiotic strategy in AECOPD or CAP+COPD patients? Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients Year: 2015
The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007
Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021
Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1902111; 10.1183/13993003.02111-2019 Year: 2019
Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019
Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis Source: Eur Respir J 2008; 31: 1068-1076 Year: 2008
Improving outcome in elderly patients with pneumonia Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005
Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006
Which COPD patient is expected to benefit from rehabilitation and which one is not? Are all COPD patients equally eligible for a rehabilitation programme? Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011